UK Medicinal Cannabis ACMD Review
UK Law and What Comes Next
UK medicinal cannabis is back under scrutiny as the Advisory Council on the Misuse of Drugs (ACMD) reviews the reforms introduced in 2018. Patients, clinicians and policymakers want to know whether the system delivers appropriate access and protects patients. There is now a fresh update on when the council expects to publish its findings.
Latest position: In its 21 September 2026 work programme update, the ACMD said the working group was concluding its report. It expects publication by the end of 2026. That is an expected timeframe, not a confirmed release date or an announcement of new law.
This guide explains the review, the current legal framework and the questions to ask when the report arrives. For the broader background, see our Medical Cannabis 2026 overview.
In this guide
UK medicinal cannabis: where is the ACMD report?
On 17 September, Business of Cannabis examined the wait for the ACMD report. Its coverage raised an important question: when would the review move from an ongoing exercise to published advice?
Four days later, the council supplied a new timetable. Its autumn update places the report among work expected before the year ends. As of this article’s review date, that update describes work nearing completion rather than published recommendations.
The distinction matters. A timetable tells readers when advice may arrive. It does not tell us what the council will recommend, whether ministers will accept that advice or when any resulting changes could take effect.
How the review reached this point
- 2 June 2025: The government commissioned a fresh assessment of the effects of the 2018 reforms.
- 17 September to 17 October 2025: The ACMD invited evidence through a public call.
- 11 March 2026: Its work programme listed the review as ongoing, with completion expected in summer 2026.
- 21 September 2026: The autumn update gave the later publication expectation described above.
The March work programme referred to completion, while the September update refers to publication. Neither should be treated as a statutory deadline. Equally, a changed timetable does not establish why the work has taken longer.
What is the UK medicinal cannabis review examining?
The Advisory Council on the Misuse of Drugs provides independent expert advice to government. Its role includes advice about drug controls. It does not act as a prescribing clinic or make treatment decisions for individual patients.
The June 2025 commissioning letter asks whether the 2018 changes achieved their intended effects and whether unintended consequences have emerged. It also asks whether private prescription availability has reduced incentives for clinical trials. Those trials could support the development of safe, effective and cost-effective products for NHS use.
Crucially, that last point is a question for investigation. It is not a finding that private clinics have obstructed research. The final report will need to explain what evidence supports its conclusions.
The public call for evidence sought input from patients, families, healthcare professionals, researchers and other stakeholders. This gives the review a route to hear different experiences. However, submissions do not automatically become recommendations, and the number of submissions cannot by itself prove a treatment works.
How should readers judge the evidence?
A useful report should make its reasoning visible. For example, patient accounts can identify problems with access or continuity of care. Clinical studies can address different questions about benefits, adverse effects and treatment comparisons. Readers should look at what each source can establish.
Our editorial test is straightforward: does a recommendation follow from the evidence described? If a report identifies uncertainty, that uncertainty should remain visible in the headline. Neither enthusiastic marketing nor blanket dismissal helps readers understand a complex clinical debate.
UK medicinal cannabis law: what changed in 2018?
From 1 November 2018, reforms created a controlled prescribing route for qualifying cannabis-based products for medicinal use in humans, commonly shortened to CBPMs. The Home Office’s explanation of the reforms sets out the specialist prescribing restrictions and the move into Schedule 2 in Great Britain.
However, the reforms did not legalise recreational cannabis or remove controls on cultivation. A person’s intention to use cannabis medicinally does not, on its own, make possession or growing lawful.
Class B and Schedule 2 mean different things
Cannabis remains a Class B controlled drug under the Misuse of Drugs Act 1971. Scheduling deals with a different question: the controls governing legitimate activities such as prescribing, supply and possession.
The Home Office cannabinoid factsheet explains that qualifying CBPMs sit in Schedule 2. Certain named licensed medicines have separate scheduling arrangements. Therefore, “medical cannabis” should not be treated as one identical product or one universal set of permissions.
For readers, the practical question is whether the specific medicine and its supply comply with the applicable rules. A broad statement that cannabis is “legal for medical use” leaves too much unexplained.
Unlicensed medicines are not automatically unlawful
In medicines regulation, “unlicensed” generally means a product lacks a marketing authorisation. That is different from saying that no lawful route exists to supply it.
The MHRA’s guidance on unlicensed medicines covers products supplied through the regulated “specials” framework, including CBPMs. Its requirements concern manufacturing, importing, distributing and supplying these medicines. The framework also identifies who may procure unlicensed CBPMs.
Consequently, readers should separate a medicine’s authorisation status from the licences and professional duties involved in its supply. Calling a product unlicensed does not establish that it is unregulated. Conversely, lawful supply does not prove that it will benefit every patient.
Why does UK medicinal cannabis access remain contentious?
The legal route and day-to-day access are separate issues. The NHS medical cannabis guidance explains that only a small number of people in England are likely to receive an NHS prescription. It describes specific circumstances involving severe epilepsy, chemotherapy-related sickness and multiple sclerosis symptoms, usually after other treatments have not helped.
In other words, the existence of a legal medicine does not create a general entitlement to an NHS prescription. Treatment decisions must address the particular medicine, condition and patient.
NHS and private prescribing raise different questions
A government answer published on 9 September 2026 acknowledged the financial burden that private treatment can place on patients. It also explained that private medicinal cannabis clinics in England must register with the Care Quality Commission and meet relevant standards.
That statement concerns England’s regulator; readers elsewhere in the UK should check the regulator for their nation. Registration is an important check, but it is not a guarantee of a prescription or a particular outcome.
If your question concerns the application process, our guide to getting medical cannabis in the UK covers NHS and private routes. This article focuses on the policy review rather than repeating those steps.
What should patients ask while the review continues?
- What evidence supports this treatment for my circumstances?
- What alternatives should we consider?
- What are the likely costs, including follow-up appointments?
- How will the clinician assess benefit and monitor adverse effects?
- Who should I contact if treatment causes problems?
These questions remain useful whatever the eventual policy response. Patients should discuss treatment changes with their clinician rather than act on predictions about the review.
Safety also remains relevant. The NHS describes possible adverse effects and interactions with other medicines. A prescription does not make a medicine risk-free, and an online testimonial cannot replace an individual assessment.
What could happen after the ACMD review?
For UK medicinal cannabis, publication will be an important checkpoint. However, a report and an implemented policy are different stages. Readers should look for a government response, the exact measures proposed and any formal implementation dates.
| Stage | What to check |
|---|---|
| ACMD report | What does the evidence show, and what advice does the council give? |
| Government response | Which recommendations do ministers accept, reject or leave under consideration? |
| Implementation | Do any changes require legislation, revised guidance or further work? |
| Patient impact | What actually changes in prescribing, service provision or costs? |
This is a framework for assessing future news, not a forecast of the report’s contents. At present, it would be premature to promise wider NHS access, lower private costs or a change in drug classification.
Does the review mean patients will be allowed to grow cannabis?
No permission to cultivate follows from the review. In a separate 9 September parliamentary answer about cultivation, the Home Office said the commission had not specifically excluded that subject. The council could consider it if relevant to its work.
That describes the possible scope of an advisory review. It neither authorises home growing nor confirms that the report will recommend it. Our article on growing cannabis in the UK explains the associated legal and safety issues.
Is retail CBD part of the same prescription system?
Retail CBD products and prescribed medicines should not be treated as interchangeable. The Home Office factsheet distinguishes pure CBD from controlled cannabinoids, but the composition and intended use of a finished product still matter.
A product’s availability in a shop does not demonstrate that it has approval to treat a medical condition. For our approach to product information and responsible claims, read the UK Compliance and Laboratory Testing Statement.
Our editorial view on UK medicinal cannabis
The most useful debate asks how to combine appropriate access, credible evidence and careful oversight. It should take patients’ experiences seriously while examining claims with the same care applied to other medicines.
For now, judge developments by published documents rather than speculation. When the report arrives, the important questions will be what it recommends, why it recommends it and how government responds.
Frequently asked questions
What does UK medicinal cannabis mean?
It is a broad phrase for cannabis-related medicines used within the UK’s medical framework. The formal term CBPM has a specific legal definition. Different products can have different authorisation and scheduling arrangements.
Has the ACMD medicinal cannabis report been published?
As of 22 September 2026, the latest official update describes the report as nearing completion, with publication expected by the end of 2026. It does not provide a specific release date.
Does the ACMD review change the law immediately?
No. The council provides advice. Publication alone does not amend legislation, guarantee NHS funding or change an individual patient’s prescription.
Is medical cannabis available on the NHS?
Yes, in limited circumstances. NHS guidance describes particular indications and specialist assessment. This does not mean that every cannabis-based medicine is routinely available for every condition.
Is an unlicensed cannabis medicine illegal?
Not necessarily. The MHRA provides a lawful framework for supplying certain unlicensed medicines. The relevant prescribing, supply and controlled-drug requirements must still be met.
Will the review allow patients to grow their own cannabis?
The review creates no such permission. Discussion of cultivation within its possible scope is not a change in the law.
Can CBD bought online replace prescribed treatment?
Do not substitute a retail product for prescribed treatment without discussing it with your clinician. Retail CBD and prescription medicines are different categories, and cannabinoid products can interact with medicines.
Where should I check for reliable updates?
Start with the ACMD’s official publications and the government’s response. For personal treatment questions, consult an appropriately qualified clinician. Check the date of any article before relying on its account of the review.
Editorial Compliance Statement
This article provides general educational and policy information. It does not provide medical or legal advice, recommend a treatment or offer prescriptions. Weed Supermarket does not diagnose conditions, prescribe medicines or replace professional healthcare advice. No product sold by Weed Supermarket should be assumed to be an approved medicine because this article discusses medicinal cannabis.
We have distinguished official announcements, current guidance and editorial interpretation. Policy proposals do not become law merely through publication. Legal and regulatory requirements can change, and individual circumstances require qualified advice. Sources and review status were checked on the date shown above.
